15 results about "Immune reactivity" patented technology

The invention relates to a hybridoma cell strain secreting a rofecoxib monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. According to the invention, a hybridoma cell strain secreting the rofecoxib monoclonal antibody is obtained through screening by preparing a rofecoxib complete antigen and carrying out animal immune reaction and cell fusion steps, the hybridoma cell strain is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46734. The monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity, the IC50 value to rofecoxib is 20.0 ng / mL, the cross reaction rate to various rofecoxib functional analogues is smaller than 1%, the monoclonal antibody can be applied to preparation of rofecoxib detection products, and an efficient detection method and means are provided for detection of rofecoxib residues in food.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

The invention relates to an application of an RIPK2 inhibitor GSK2983559 in preparation of a medicine for preventing, treating and / or relieving smoke inhalation type lung injury, and the application focuses on targeted inhibition of a core inflammation signal channel of RIPK2-NF-kappa B, regulation and control of excessive activated natural immune response after smoke inhalation, alleviation of acute inflammation injury of airways and pulmonary alveoli, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury, treatment of the smoke inhalation type lung injury and / or treatment of the smoke inhalation type lung injury. And a novel targeted therapeutic drug is provided for clinically preventing and treating lung injury caused by smoke inhalation.

A conjugate obtained by binding a benzodiazepine to an antibody or an antigen-binding fragment thereof having immunological reactivity with MCEMP1 protein, the conjugate being an antibody-drug complex (ADC) having a strong anti-tumor effect and being useful for the treatment and / or prevention of cancer, particularly cancer expressing MCEMP1 protein on the cell surface.

The invention provides an immune detection method of an immune checkpoint detection kit, and belongs to the technical field of immune checkpoint detection kits.The immune detection method comprises the steps that an immune reaction system containing immune checkpoint antibodies is prepared, incubation is conducted under the constant temperature condition to form a sandwich type immune complex, and the sandwich type immune complex is obtained; phycoerythrin labeled streptavidin is added for fluorescence labeling, a flow cytometer is adopted for fluorescence signal detection after interference substances are removed through multiple times of cleaning, fluorescence image data are processed through an image partitioning optimization model, image processing parameters are dynamically adjusted through a signal enhancement algorithm function and a gating weight function, and the fluorescence image is obtained. A multi-scale feature extraction network based on a visual converter architecture is adopted to realize accurate processing of a complex fluorescence image, finally correlation analysis and matrix decomposition calculation are performed on fluorescence intensity data, and a detection analysis model is established to output index concentration values of immune checkpoints. The problem that complex fluorescence image data are difficult to process accurately at present is solved.

Provided herein are methods for activating an immune cell in a subject. In some embodiments, the methods comprise passing an immune cell from a subject through an immune modulating chamber comprising a tumor cell, thereby activating the immune cell, and returning the activated immune cell to the subject. In some embodiments, the methods further comprise isolating an immune cell-containing portion of a sample and passing the immune cell-containing portion through the immune modulating chamber. Methods of treating cancer and methods of inducing an immune response against a tumor are also provided herein.

The present invention provides a novel CAR design containing a modified CD3ζ chain, and cells containing genetically modified immune-responsive cells (e.g., T cells, NK cells, or CTL cells) containing the CAR. [Solution] This disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. The CAR can bind to a tumor antigen or a pathogen antigen. In certain non-limiting embodiments, the CAR comprises an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide.

An immunoresponsive cell, such as a T-cell expressing(i) a second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; and(ii) a chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

Providing a fusosome composition for T cell delivery. [Solution] This disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity to target cells, e.g., one or more fusogens, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome composition comprises one or more modifications that reduce the immune response to the fusosome.

The present invention relates to a pharmaceutical composition for treatment and / or prevention of cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with a CAPRIN-1 protein or a fragment thereof comprising 7 or more consecutive amino acids.

An immunoresponsive cell, such as a T-cell expressinga second generation chimeric antigen receptor comprising:(a) a signalling region;(b) a co-stimulatory signalling region;(c) a transmembrane domain; and(d) a binding element that specifically interacts with a first epitope on a target antigen; anda chimeric costimulatory receptor comprising(e) a co-stimulatory signalling region which is different to that of (b);(f) a transmembrane domain; andg) a binding element that specifically interacts with a second epitope on a target antigen.This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

The invention discloses a magnetic bead-bicolor quantum dot premixed host-guest encoding microsphere, a preparation method thereof and a multivariate analysis kit, bicolor hydrophobic quantum dots are premixed and assembled into dendritic silicon dioxide dSiO2, and the color proportion is regulated and controlled through premixing to prepare an encoding guest sphere. The main sphere is a 5-micron polystyrene sphere filled with superparamagnetic particles, a large number of object spheres are coupled to the surface of the main sphere through a statistical averaging effect, the fluctuation (standard deviation) of an integrally output coding signal (blue / red intensity ratio) is small, and the uniformity of the coding signal is improved. Meanwhile, small-size hollow silicon dioxide nanotubes are used for loading green quantum dots, so that the immunoreaction kinetics of the detection probe is improved. A core-satellite structure immune complex is formed by full quantum dot narrow emission under unitary excitation (405nm), blue-red double colors are used as coding colors, green is used as signal colors, coding multivariate analysis is carried out, and high-sensitivity and high-accuracy imaging quantitative analysis can be realized on various respiratory tract pathogen antigens.

The present disclosure relates to the fields of adoptive cell therapy and treatments for autoimmune diseases and disorders. The present disclosure provides engineered cells, compositions, and methods for treating patients suffering from autoimmune disorders and which are poorly treated by other methods. Specifically, the engineered cells, compositions, and methods selectivity destroy cells that mediate autoimmunity, both B and T cells, yet spare cells that modulate the autoimmune inflammatory response, e.g., regulatory T cells, or are not otherwise involved in the autoimmune response. Finally, the engineered cells are designed to avoid fratricide during their manufacturing.

An object of the present invention is to identify cancer antigen proteins specifically expressed on the surface of cancer cells and to provide a use of antibodies targeting such proteins as therapeutic and / or preventive agents for cancer. The present invention relates to, for example, a pharmaceutical composition for treatment and / or prevention of a cancer, which comprises, as an active ingredient, an antibody or fragment thereof having an immunological reactivity with an MCEMP1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOS: 2 to 8 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence, or with a fragment of the MCEMP1 protein comprising 7 or more consecutive amino acids.